Volume 123, Issue 11 pp. 920-929
Review Article

A clinical and molecular review of inverted papilloma of the urinary tract: how to handle?

Peter Hjorth Jørgensen

Corresponding Author

Peter Hjorth Jørgensen

Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark

Peter Hjorth Jørgensen, Nordre Fasanvej 57, 2000 Frederiksberg C, Denmark. e-mail: [email protected]Search for more papers by this author
Ben Vainer

Ben Vainer

Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
Gregers Gautier Hermann

Gregers Gautier Hermann

Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
First published: 11 September 2015
Citations: 3

Abstract

Inverted papilloma (IP) of the urinary tract is classified by the World Health Organisation as a non-invasive urothelial tumour with normal to minimal cytological atypia of the neoplastic cells. During the 1980s, it came under suspicion of having a premalignant or malignant potential and of being concurrent with urothelial cell carcinoma (UCC). This quandary has been proven difficult to solve, due to the fact that IP is very rare and literature mostly consists of case reports with varying levels of information, making strong meta-analyses problematic. New immunohistochemical techniques and genetic approaches are more frequently being used in the attempt to achieve better classifications, prognosis and treatment of lesions hereunder IP. This review will, in our awareness, be the first to combine the knowledge from retrospective studies with these new approaches for determining a possible premalignant potential and concurrency with UCC and subsequently outline a recommendation for follow-up.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.